ZURICH (Reuters) -Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the United States against Amgen over the alleged entrenchment of the market position of ...

Sandoz has filed an antitrust lawsuit in the United States against Amgen, for extending and entrenching the dominant market position of its blockbuster medicine, Enbrel (etanercept). The drug was ...

Sandoz signs 10-year agreement with partner Delpharm, a global pharmaceutical developer and contract manufacturer Agreement will secure a reliable supply of affordable, quality sterile injectables ...

The presence of dysregulation profile in children with ADHD was associated with higher sleep disturbances following treatment with methylphenidate. Children with ...

Results showed no significant increase in adverse event risk with use of SSRI plus methylphenidate in adults with ADHD and depression. Risk of headache was lower with combined SSRI and ...

A pilot study conducted by Kessler Foundation researchers has shown promising results in the use of methylphenidate to enhance oculomotor function in individuals with multiple sclerosis (MS).

The FDA on Tuesday approved two Sandoz drugs as interchangeable with and approved for all uses of the Amgen products. The Amgen antibody, denosumab, is marketed as Prolia for the treatment of ...

Bangalore-based Biocon Biologics Ltd (BBL) announced a new partnership with Sandoz AG to promote, sell and distribute two of its cancer biosimilars - Trastuzumab and Bevacizumab - in Australia.

Sandoz (OTCMKT:SDZNY) stock is a hot topic among traders on Wednesday as the company starts trading after a spinoff. Let’s get into everything investors need to know about Sandoz below! What to ...